新型癌症干细胞标志物及其在原发性人类胶质瘤分级中的适用性
Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.
作者信息
Dolgova Evgeniya V, Mishinov Sergey V, Proskurina Anastasiya S, Potter Ekaterina A, Efremov Yaroslav R, Bayborodin Sergey I, Tyrinova Tamara V, Stupak Vyacheslav V, Ostatin Alexandr A, Chernykh Elena R, Bogachev Sergey S
机构信息
1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
2 First Department of Neurosurgery, Ya. L. Tsivian Novosibirsk Research Institute of Traumatology and Orthopaedics, Novosibirsk, Russia.
出版信息
Technol Cancer Res Treat. 2018 Jan 1;17:1533034617753812. doi: 10.1177/1533034617753812.
Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates ( R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).
包括肿瘤起始干细胞在内的低分化细胞群体已被证明具有天然内化双链DNA片段的独特能力。利用这一特征作为标记，我们发现来自活检组织的0.1%至6%的人类胶质母细胞瘤细胞能够有效地内化荧光标记的DNA探针。其中，使用3名患者的样本，66%至100%的细胞对CD133也呈阳性，CD133是一种公认的肿瘤起始胶质瘤干细胞表面标记。使用原发性恶性脑病变（33名患者）的样本，我们证明肿瘤分级与DNA内化细胞的百分比显著相关（R = 0.71）。而复发样本（18名患者）未观察到这种相关性。
Zotero 插件